6d
GlobalData on MSNTrevi’s Phase IIb chronic cough success spikes stock by 71%The company’s trial of Haduvio met its primary and secondary endpoints in reducing coughing fits across patients by 53%.
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that ...
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to ...
GOTHENBURG, SE / ACCESS Newswire / March 12, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, March 12, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and ...
GOTHENBURG, SE / ACCESS Newswire / March 12, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, March 12, 2025 - IRLAB Therapeutics AB , a company discovering and developing novel ...
The Phase Ib and Phase IIa studies showed a good safety and tolerability ... effect compared with current treatment options. A Phase IIb study, completed in 2023, showed that mesdopetam has ...
ViiV Healthcare, majority owned by GSK (GSK), with Pfizer (PFE) (PE) and Shionogi as shareholders, announced findings from the company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results